CriticalClass III antiarrhythmics (Vaughan Williams)×Antiretroviral, HIV protease inhibitor
Updated · Methodology
Mechanism
In the liver, CYP3A4 converts amiodarone mainly into its active metabolite desethylamiodarone (amiodarone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Atazanavir inhibits this enzyme, so amiodarone levels can rise (atazanavir SmPC, European Medicines Agency, EMA). Ritonavir inhibits CYP3A4 more strongly than atazanavir itself, and cobicistat is also a potent CYP3A inhibitor. The atazanavir/cobicistat SmPC contraindicates amiodarone because of its narrow therapeutic margin (atazanavir and atazanavir/cobicistat SmPCs, EMA). Amiodarone has a long half-life of 20–100 days, and its interactions can persist for several months after it is stopped (amiodarone SmPC, AEMPS). Amiodarone itself inhibits CYP3A4 (AEMPS), but the documents give no data on its effect on atazanavir and no figures for this pair.
Symptoms
According to the US atazanavir label, the combination in regimens with ritonavir may cause serious or life-threatening reactions such as cardiac arrhythmias (atazanavir label, US Food and Drug Administration, FDA). Amiodarone can worsen existing arrhythmias or cause new ones, including ventricular fibrillation and polymorphic ventricular tachycardia with prolongation of the heart-rate-corrected QT interval (QTc), that is, torsade de pointes. In 2–4% of patients, it causes symptomatic bradycardia or sinus arrest (FDA amiodarone label). In some people atazanavir prolongs the PR interval: atrioventricular conduction changes are usually asymptomatic and generally limited to first-degree block, but second-degree block has also been reported (atazanavir FDA label). Adverse reactions to amiodarone are usually dose-related (amiodarone summary of product characteristics, Spanish Agency of Medicines and Medical Devices, AEMPS), and QT and PR prolongation show only on an electrocardiogram (ECG).
Management
The combination is contraindicated. The US atazanavir label contraindicates amiodarone in regimens with ritonavir (atazanavir label, US Food and Drug Administration, FDA). The atazanavir/cobicistat summary of product characteristics (SmPC) contraindicates it in regimens with cobicistat, including the combined tablet (atazanavir/cobicistat SmPC, European Medicines Agency, EMA). Under the European SmPC, atazanavir is taken with low-dose ritonavir. Unboosted atazanavir 400 mg is kept only for restricted cases after ritonavir is stopped (atazanavir SmPC, EMA). The European documents differ here. The atazanavir SmPC does not list amiodarone among the contraindications, and its interaction table advises caution and concentration monitoring. The ritonavir SmPC contraindicates amiodarone, but when ritonavir is used as a booster, it refers to the contraindications of the protease inhibitor (atazanavir and ritonavir SmPCs, EMA). If atazanavir is used without a booster in these restricted cases, the US label advises caution and monitoring of amiodarone concentrations for that regimen. It notes that the combination has not been studied and may cause serious or life-threatening reactions (atazanavir FDA label). The amiodarone documents recommend avoiding CYP3A4 inhibitors throughout treatment (amiodarone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and FDA label). Amiodarone interactions can persist for several months after it is stopped (AEMPS). No document states how long to wait after amiodarone before starting boosted atazanavir. Take special precautions when atazanavir is given with drugs that may prolong the QT interval (atazanavir SmPC, EMA). Amiodarone itself prolongs QT (amiodarone SmPC, AEMPS). Before starting amiodarone, the amiodarone SmPC recommends an electrocardiogram (ECG) and a potassium test. Correct low potassium beforehand (AEMPS), and low magnesium and calcium as well (amiodarone FDA label). Stop amiodarone if second- or third-degree atrioventricular block, sinoatrial block or bifascicular block develops (AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Reyataz (atazanavir) prescribing information (2024)– DailyMed setid 165cff62-b284-4a27-a65d-9ec8a5bfcdd8, revisión 12/2024, secciones 4 y 7.3
- EMA: Ficha técnica: Ritonavir (EU/1/96/016), sección 4.3 (2026)– EMA, Norvir, ficha técnica en CIMA (nº registro 96016005), consultada 03.10.2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Amiodarona, Trangorex 200 mg (nº registro 48048), secciones 4.3, 4.4 y 4.5 (2022)– AEMPS, CIMA, nº registro 48048, revisión 08/2022, secciones 4.3, 4.4 y 4.5
- FDA: Pacerone (amiodarone) prescribing information (2025)– FDA, DailyMed setid 4c4ec9b0-13a5-49a8-b57b-b3f64e4316a7 (Upsher-Smith Laboratories), version 27, revised 07/2025, sections 5.4 and 7 (Table 1)
- EMA: Ficha técnica: Atazanavir, Reyataz (EU/1/03/267), sección 4.2 (2026)– EMA, Reyataz 300 mg cápsulas (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 03267008, consultada 10/2026, secciones 4.2, 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Atazanavir/cobicistat, Evotaz (EU/1/15/1025), sección 4.3 (2026)– EMA, Evotaz 300 mg/150 mg comprimidos (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151025001, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5